Colonial Trust’s Royalty Pharma RPRX Stock Holding History

Colonial Trust’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-304	Closed	-$7.75K	–	1300
2024 Q4	$7.75K	Buy	+304	New	+$8.06K	﹤0.01%	989

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Colonial Trust's RPRX Position: Q1 2025 in Review

Colonial Trust sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 304 shares — an estimated $7.75K sold.

Colonial Trust first reported a position in RPRX in Q4 2024 and held it in 1 quarter. The position peaked at $7.75K in Q4 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

Colonial Trust reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
Colonial Trust sold 304 Royalty Pharma shares in Q1 2025, an estimated $7.75K.
Colonial Trust first reported a position in Royalty Pharma in Q4 2024 and held it in 1 quarter.
Colonial Trust's Royalty Pharma position peaked at $7.75K in Q4 2024.
447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Colonial Trust's 13F filing for Q1 2025, filed 14 May 2025.